[4] Ramaswamy's initial strategy was to in-license drug candidates and create subsidiaries focused on distinct therapeutic areas.

Roivant built and launched Datavant, which allows healthcare institutions to share data, and was merged with Coix[8] to become a US$7 billion company.

Roivant's technology portfolio also includes Lokavant, which integrates clinical trial data to identify and mitigate risks in pharmaceutical development.

Later that year in December 2022, Roivant and Pfizer announced [24] their third partnership to create a new Vant [25] focused on developing TL1A drug candidates for inflammatory and fibrotic diseases.

[26] Axovant, owned by Roivant's Sio Gene Therapies, which failed testing in the end, has been accused of being a pump-and-dump scheme.

[27][28][29][30] In December 2023, Roche completed the acquisition of Telavant from Roivant for a purchase price of $7.1 billion upfront and a near-term milestone payment of $150 million.

[45] In March 2020, Roivant announced it is developing gimsilumab, an anti-granulocyte-macrophage colony-stimulating factor (anti-GM-CSF) monoclonal antibody to prevent and treat acute respiratory distress syndrome (ARDS) in patients with COVID-19.